Publication - Advice and guidance

Coronavirus (COVID-19): clinical guidelines for managing systemic anti-cancer therapy (SACT) and radiotherapy (RT) for COVID-19 positive cancer patients

This document contains guidance for clinical teams on the management of systemic anti-cancer therapy (SACT) and radiotherapy (RT) for Covid-19 positive cancer patients.

Contents
Coronavirus (COVID-19): clinical guidelines for managing systemic anti-cancer therapy (SACT) and radiotherapy (RT) for COVID-19 positive cancer patients
Overview

This document contains guidance for clinical teams on the management of SACT and RT for patients who test positive for COVID-19. It includes a situation background assessment recommendation (SBAR) report with SACT and RT treatment guidance.

It also contains guidance for the development of standard operating procedures (SOPs) for the safe delivery of SACT to COVID-19 positive patients within cancer centres/ units.

The preparation of these papers has been overseen by the SACT/RT Sub-Group with input and approval from Clinical Cell.

Date guidance came into practice

This guidance is effective from 13 April 2021 and will continue while COVID-19 presents a risk.